Naoya Iwamoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Naoya Iwamoto has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Shinya Oishi
Kyoto Pharmaceutical University
6 shared publications - Gosuke Hayashi
Department of Biomolecular Engineering, Graduate School of Engineering, Nagoya University, Nagoya, Japan
2 shared publications - Hiroshi Murakami
Department of Biomolecular Engineering, Graduate School of Engineering, Nagoya University, Nagoya, Japan
2 shared publications Katsuaki Higashi
Kyoto University
2 shared publications- Kazuya Kobayashi
Laboratory of Medicinal Chemistry, Kyoto Pharmaceutical University, Yamashina-ku, Kyoto 607-8412, Japan
2 shared publications Keisuke Aoki
Kyoto Pharmaceutical University
2 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 144
Structure–activity relationships of hybrid paraisariamide/ternatin cyclic heptapeptides
- 23 October 2026
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 144
Open AccessStructure–activity relationships of hybrid paraisariamide/ternatin cyclic heptapeptides
- 22 October 2026
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 37 (11) , 2323-2333
Chemical Synthesis of a Copepod-Derived Artificial Luciferase and Characterization of Site-specific Oxidation During Bioluminescence
Luciferases are enzymes that catalyze bioluminescent reactions: they are used widely for bioimaging and in reporter systems. Among them, copepod luciferases have distinct structures and bioluminescence profiles, but their structure(s) and mechanism(s) remain poorly understood. Chemical protein synthesis enables precise structural and functional analyses using homogeneous samples with site-specific modifications. In this study, we first investigated the chemical synthesis of picALuc, a minimal artificial luciferase derived from copepod luciferases. picALuc was successfully synthesized through sequential native chemical ligations and subsequent oxidative refolding. During analysis of the bioluminescence reaction of synthetic picALuc, we unexpectedly observed the generation of a mono-oxygenated form of the protein. To characterize the oxidation site and its impact on the luminescence properties, we designed and synthesized several picALuc variants in which the methionine residues of the protein (Met41 and Met82) were replaced with either norleucine or methionine sulfoxide. Experiments revealed that oxidation of picALuc occurred specifically at Met82. The oxygenation did not affect the rapid luminescence-decay (i.e., the “flash-type”) kinetics of picALuc. Comparative analysis of methionine sulfoxide-containing variants revealed that the position of methionine sulfoxide differentially affects the protein folding efficiency and overall hydrophilicity. These results provide valuable insights for the development of miniature luciferases with prolonged bioluminescence suitable for bioimaging applications.
- 22 October 2026
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 37 (11) , 2323-2333
Chemical Synthesis of a Copepod-Derived Artificial Luciferase and Characterization of Site-specific Oxidation During Bioluminescence
Luciferases are enzymes that catalyze bioluminescent reactions: they are used widely for bioimaging and in reporter systems. Among them, copepod luciferases have distinct structures and bioluminescence profiles, but their structure(s) and mechanism(s) remain poorly understood. Chemical protein synthesis enables precise structural and functional analyses using homogeneous samples with site-specific modifications. In this study, we first investigated the chemical synthesis of picALuc, a minimal artificial luciferase derived from copepod luciferases. picALuc was successfully synthesized through sequential native chemical ligations and subsequent oxidative refolding. During analysis of the bioluminescence reaction of synthetic picALuc, we unexpectedly observed the generation of a mono-oxygenated form of the protein. To characterize the oxidation site and its impact on the luminescence properties, we designed and synthesized several picALuc variants in which the methionine residues of the protein (Met41 and Met82) were replaced with either norleucine or methionine sulfoxide. Experiments revealed that oxidation of picALuc occurred specifically at Met82. The oxygenation did not affect the rapid luminescence-decay (i.e., the “flash-type”) kinetics of picALuc. Comparative analysis of methionine sulfoxide-containing variants revealed that the position of methionine sulfoxide differentially affects the protein folding efficiency and overall hydrophilicity. These results provide valuable insights for the development of miniature luciferases with prolonged bioluminescence suitable for bioimaging applications.
- 19 August 2026
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 37 (9) , 1845-1856
Identification of a Mirror-Image VHH Antibody with VEGF-Inhibitory Activity and Characterization of Its Immunogenicity
Immunogenicity remains a major challenge in antibody therapeutics. Antibodies can be recognized as foreign by immune cells, leading to the induction of antidrug antibodies that ultimately compromise therapeutic efficacy. This response is primarily driven by proteolytic processing within antigen-presenting cells and the subsequent presentation of peptide fragments to T cells via major histocompatibility complex molecules. As mirror-image proteins are expected to exhibit resistance to proteolytic degradation, we have been developing mirror-image VHH antibodies composed entirely of d-amino acids. Previously, we generated a d-VHH antibody with specific binding activity to vascular endothelial growth factor A (VEGF-A) and demonstrated that it did not induce antidrug IgG antibodies in a mouse model. However, this d-VHH antibody did not inhibit the VEGF–VEGF receptor interaction, and the immunological processes leading to the lack of IgG antibody induction had not been experimentally demonstrated. In this study, we constructed a new phage-displayed library to improve the hit rate and enable the efficient chemical synthesis of d-VHH antibodies. Using this library, mirror-image screening against d-VEGF identified new VHH antibody sequences with specific binding. The synthesized d-VHH antibody inhibited the VEGF–VEGF receptor interaction. Next, we investigated the immunogenicity of d-VHH antibody using a conventional l-VHH antibody as a reference. The d-VHH antibody resisted enzymatic degradation and, in a mouse model, did not induce inflammatory cytokine production, T-cell responses, or the formation of antidrug antibodies against the administered antibody. Collectively, these findings highlight the potential of inhibitory d-VHH antibodies as a promising approach for developing low-immunogenic therapeutic antibodies.
- 19 August 2026
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 37 (9) , 1845-1856
Identification of a Mirror-Image VHH Antibody with VEGF-Inhibitory Activity and Characterization of Its Immunogenicity
Immunogenicity remains a major challenge in antibody therapeutics. Antibodies can be recognized as foreign by immune cells, leading to the induction of antidrug antibodies that ultimately compromise therapeutic efficacy. This response is primarily driven by proteolytic processing within antigen-presenting cells and the subsequent presentation of peptide fragments to T cells via major histocompatibility complex molecules. As mirror-image proteins are expected to exhibit resistance to proteolytic degradation, we have been developing mirror-image VHH antibodies composed entirely of d-amino acids. Previously, we generated a d-VHH antibody with specific binding activity to vascular endothelial growth factor A (VEGF-A) and demonstrated that it did not induce antidrug IgG antibodies in a mouse model. However, this d-VHH antibody did not inhibit the VEGF–VEGF receptor interaction, and the immunological processes leading to the lack of IgG antibody induction had not been experimentally demonstrated. In this study, we constructed a new phage-displayed library to improve the hit rate and enable the efficient chemical synthesis of d-VHH antibodies. Using this library, mirror-image screening against d-VEGF identified new VHH antibody sequences with specific binding. The synthesized d-VHH antibody inhibited the VEGF–VEGF receptor interaction. Next, we investigated the immunogenicity of d-VHH antibody using a conventional l-VHH antibody as a reference. The d-VHH antibody resisted enzymatic degradation and, in a mouse model, did not induce inflammatory cytokine production, T-cell responses, or the formation of antidrug antibodies against the administered antibody. Collectively, these findings highlight the potential of inhibitory d-VHH antibodies as a promising approach for developing low-immunogenic therapeutic antibodies.
- Open Access
- 13 May 2026
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
Identification and structure–activity relationship analysis of minimal fusion inhibitors targeting measles virus F protein
Optimization of a measles virus HR2-derived fusion inhibitor yielded a short peptide with potent antiviral activity and revealed key residues governing interactions with HR1.
- 13 May 2026
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
Open AccessIdentification and structure–activity relationship analysis of minimal fusion inhibitors targeting measles virus F protein
Optimization of a measles virus HR2-derived fusion inhibitor yielded a short peptide with potent antiviral activity and revealed key residues governing interactions with HR1.
- 21 June 2025
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 36 (7) , 1504-1515
Design and Evaluation of Stable Cysteine-Modified Monobody Scaffolds for Mirror-Image Synthesis
Mirror-image proteins (d-proteins) are promising therapeutic molecules with high biological stability and low immunogenicity. We recently developed a novel d-monobody scaffold variant with reduced immunogenicity. This variant incorporates two cysteine substitutions that enable the chemical synthesis of d-monobodies via native chemical ligation. In this study, the structure-activity relationship of monobody scaffold variants was investigated to identify more suitable positions for cysteine modifications. Several monobody variants with different cysteine substitution patterns and additional cysteine-selective modifications were designed and synthesized. Comprehensive functional analysis of the synthetic monobody derivatives led to the identification of a favorable monobody scaffold with potent target binding and high thermal stability. The optimized monobody scaffold with a cysteine cross-linker was used to develop d-monobody with additional functional groups.
- 21 June 2025
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 36 (7) , 1504-1515
Design and Evaluation of Stable Cysteine-Modified Monobody Scaffolds for Mirror-Image Synthesis
Mirror-image proteins (d-proteins) are promising therapeutic molecules with high biological stability and low immunogenicity. We recently developed a novel d-monobody scaffold variant with reduced immunogenicity. This variant incorporates two cysteine substitutions that enable the chemical synthesis of d-monobodies via native chemical ligation. In this study, the structure-activity relationship of monobody scaffold variants was investigated to identify more suitable positions for cysteine modifications. Several monobody variants with different cysteine substitution patterns and additional cysteine-selective modifications were designed and synthesized. Comprehensive functional analysis of the synthetic monobody derivatives led to the identification of a favorable monobody scaffold with potent target binding and high thermal stability. The optimized monobody scaffold with a cysteine cross-linker was used to develop d-monobody with additional functional groups.
- Open Access
- 23 December 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-11
Generating a mirror-image monobody targeting MCP-1 via TRAP display and chemical protein synthesis
Biologically produced protein drugs are generally susceptible to degradation by proteases and often exhibit immunogenicity. To address this issue, mirror-image peptide/protein binders consisting of D-amino acids have been developed so far through the mirror-image phage display technique. Here, we develop a mirror-image protein binder derived from a monobody, one of the promising protein scaffolds, utilizing two notable technologies: chemical protein synthesis and TRAP display, an improved version of mRNA display. A sequential workflow of initial screening followed by affinity maturation, facilitated by TRAP display, generates an L-monobody with high affinity (KD = 1.3 nM) against monocyte chemoattractant protein-1 (MCP-1) D-enantiomer. The chemically synthesized D-monobody demonstrates strong and specific binding to L-MCP-1 and exhibits pharmaceutically favorable properties such as proteolytic resistance, minimal immune response, and a potent inhibitory effect on MCP-1-induced cell migration. This study elevates the value of mirror-image peptide/protein binders as an alternative modality in drug discovery.
- 23 December 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-11
Open AccessGenerating a mirror-image monobody targeting MCP-1 via TRAP display and chemical protein synthesis
Biologically produced protein drugs are generally susceptible to degradation by proteases and often exhibit immunogenicity. To address this issue, mirror-image peptide/protein binders consisting of D-amino acids have been developed so far through the mirror-image phage display technique. Here, we develop a mirror-image protein binder derived from a monobody, one of the promising protein scaffolds, utilizing two notable technologies: chemical protein synthesis and TRAP display, an improved version of mRNA display. A sequential workflow of initial screening followed by affinity maturation, facilitated by TRAP display, generates an L-monobody with high affinity (KD = 1.3 nM) against monocyte chemoattractant protein-1 (MCP-1) D-enantiomer. The chemically synthesized D-monobody demonstrates strong and specific binding to L-MCP-1 and exhibits pharmaceutically favorable properties such as proteolytic resistance, minimal immune response, and a potent inhibitory effect on MCP-1-induced cell migration. This study elevates the value of mirror-image peptide/protein binders as an alternative modality in drug discovery.